Preferences help
enabled [disable] Abstract
Number of results
2012 | 7 | 1 | 95-99
Article title

Arterial hypertension in degenerative non-severe aortic stenosis

Title variants
Languages of publication
Physical description
1 - 2 - 2012
24 - 11 - 2011
  • Department of Cardiac Surgery, Chair of Cardiology and Cardiac Surgery, Medical University of Lodz, 91-425, Lodz, Poland
  • Department of Cardiac Surgery, Chair of Cardiology and Cardiac Surgery, Medical University of Lodz, 91-425, Lodz, Poland
  • Department of Cardiology, Chair of Cardiology and Cardiac Surgery, Medical University of Lodz, 91-425, Lodz, Poland
  • [1] Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al. Guidelines on the management of valvular heart disease. The Task Force of management of valvular heart disease of the European Society of Cardiology. Eur Heart J 2007,28,230–268
  • [2] Lindross M, Kupari M, Heikkila J, Tilvis R. Prevalences of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993,21,1220–1225[Crossref]
  • [3] Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005,111,3316–3326[Crossref]
  • [4] O’Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in morphologically early lesion of “degenerative” valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996,16,523–532[Crossref]
  • [5] Breyne J, Juthier F, Corseaux D, Marechaux S, Zawadzki C, Jeanpierre E, et al. Atherosclerotic-like process in aortic stenosis: Activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration. Atherosclerosis 2010,213,369–376[Crossref][WoS]
  • [6] Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997,29,630–634[Crossref]
  • [7] Briand M, Dumesnil JG, Kadem L, Tongue AG, Rieu R, Garcia D, et al. Reduced systemic arterial compliance impacts siginificantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. J Am Coll Cardiol 2005,46,291–298[Crossref]
  • [8] Conroy R, Pyorala K, Fitzgerald A, Sans S, Menotti A, De Backer G, et al.; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003,24,987–1003[Crossref]
  • [9] Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice; executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007,28,2375–2414[Crossref]
  • [10] Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, Howard Wm J, et al. Program (NCEP) Expert Panel and Detection, Evaluation, and Treatment of High Blood, Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106,3143–3421[Crossref]
  • [11] De Finis A, Di Napoli P, Gaeta MA, Gaeta F, Gallina S, Gallina A, et al. Characteristics and clinical course of degenerative aortic stenosis in the elderly. Cardiologia 1995,40,101–107
  • [12] Cuniberti LA, Stutzbach PG, Guevara E, Yannarelli GG, Laguens RP, Favaloro RR. Development of mild aortic valve stenosis in a rabbit model of hypertension. J Am Coll Cardiol 2006,47,2303–2309[Crossref]
  • [13] Kadem L, Dumesnil JG, Rieu R, Durand LG, Garcia D, Pibarot P. Impact of systemie hypertension on the assessment of aortic stenosis. Heart 2005,91,354–361[Crossref]
  • [14] Carabello BA. Aortic stenosis. N Engl J Med 2002,346,677–682[Crossref]
  • [15] Dumesnil JG, Pibarot P, Carabello B. Paradoxical low flow and/or low gradient severe aortic stenosis despite preserved left ventricular ejection fraction: implications for diagnosis and treatment. Eur Heart J 2010,31,281–289s[Crossref]
  • [16] Hachicha Z, Dumesnil J, Bogaty P, Pibarot P. Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival. Circulation 2007,115,2856–2864[Crossref][WoS]
  • [17] Galante A, Pietroiusti A, Vellini M, Piccolo P, Possati G, De Bonis M, et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001,38,1078–1082[Crossref]
  • [18] Sánchez PL, Santos JL, Kaski JC, Cruz I, Arribas A, Villacorta E, et al. Grupo AORTICA (Grupo de Estudio de la Estenosis Aórtica). Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am J Cardiol 2006,97,90–93.[Crossref]
  • [19] Jeevanantham V, Singh N, Izuora K, D’souza JP, Hsi DH. Correlation of high sensitivity C-reactive protein and calcific aortic valve disease. Mayo Clin Proc 2007,82,171–174[Crossref]
  • [20] Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implication of secondary prevention. Circulation 2000,101,2497–502 [Crossref]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.